Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ondansetron

FDA-approved product (tablet, orally disintegrating, oral), marketed as Ondansetron, Zofran Odt, Zuplenz and 6 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ondansetron
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Chemotherapy-induced nausea and vomiting
  • Nausea
  • Nausea and vomiting
  • Post operative nausea and vomiting
  • Radiation-induced nausea and vomiting
  • Vomiting

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Serotonin (5ht3) antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA45.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli26.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ondansetron in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.3 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ondansetron with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Oral Disintegrating Ondansetron Tablet to Reduce Vomiting From Gastroenteritis in a Pediatric Emergency Department

    NCT00120744 · start 2004-01

    Registered record
    Registry ID
    NCT00120744
    Conditions
    Gastroenteritis; Vomiting; Diarrhea; Dehydration
    Interventions
    Ondansetron Oral Disintegrating Tablet
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-01
    Completion
    2005-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastroenteritis; Vomiting; Diarrhea; Dehydration
    InterventionOndansetron Oral Disintegrating Tablet
    PhaseNot applicable
    Registry statusCompleted

  • Ondansetron HCl Orally Disintegrating Tablets Under Non-Fasting Conditions

    NCT00934921 · start 2003-02

    Registered record
    Registry ID
    NCT00934921
    Conditions
    Healthy
    Interventions
    Ondansetron; Zofran®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2003-02
    Completion
    2003-02
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionOndansetron; Zofran®
    PhasePhase 1
    Registry statusCompleted

  • Ondansetron Reduce Vomiting Associated With Ketamine PSA

    NCT00387556 · start 2002-12

    Registered record
    Registry ID
    NCT00387556
    Conditions
    Conscious Sedation
    Interventions
    Ondansetron
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2002-12
    Completion
    2006-12
    Enrolment
    268

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConscious Sedation
    InterventionOndansetron
    PhaseNot applicable
    Registry statusCompleted

  • Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer

    NCT00020657 · start 2001-07

    Registered record
    Registry ID
    NCT00020657
    Conditions
    Nausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    dolasetron mesylate; granisetron hydrochloride; ondansetron; prochlorperazine; quality-of-life assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-07
    Completion
    2004-10
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNausea and Vomiting; Unspecified Adult Solid Tumor, Protocol Specific
    Interventiondolasetron mesylate; granisetron hydrochloride; ondansetron; prochlorperazine +1 more
    PhasePhase 3
    Registry statusCompleted

  • Ondansetron Treatment for Alcoholism

    NCT00000443

    Registered record
    Registry ID
    NCT00000443
    Conditions
    Alcoholism
    Interventions
    ondansetron (Zofran)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2000-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAlcoholism
    Interventionondansetron (Zofran)
    PhasePhase 2
    Registry statusCompleted